Research ArticleMinireview
A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic
Kelly A. Fader, Jiangwei Zhang, Joseph P. Menetski, Ravi I. Thadhani, Elliott M. Antman, Gary S. Friedman, Shashi K. Ramaiah and Vishal S. Vaidya
Journal of Pharmacology and Experimental Therapeutics January 2021, 376 (1) 12-20; DOI: https://doi.org/10.1124/jpet.120.000204
Kelly A. Fader
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Jiangwei Zhang
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Joseph P. Menetski
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Ravi I. Thadhani
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Elliott M. Antman
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Gary S. Friedman
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Shashi K. Ramaiah
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)
Vishal S. Vaidya
Worldwide Research, Development and Medical, Pfizer Inc., Cambridge, Massachusetts (K.A.F., J.Z., G.S.F., S.K.R., V.S.V.); Foundation for the National Institutes of Health, Bethesda, Maryland (J.P.M.); Mass General Brigham, Boston, Massachusetts (R.I.T.); and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (E.M.A.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMinireview
Biomarker-Centric Approach to Drug Development
Kelly A. Fader, Jiangwei Zhang, Joseph P. Menetski, Ravi I. Thadhani, Elliott M. Antman, Gary S. Friedman, Shashi K. Ramaiah and Vishal S. Vaidya
Journal of Pharmacology and Experimental Therapeutics January 1, 2021, 376 (1) 12-20; DOI: https://doi.org/10.1124/jpet.120.000204
Research ArticleMinireview
Biomarker-Centric Approach to Drug Development
Kelly A. Fader, Jiangwei Zhang, Joseph P. Menetski, Ravi I. Thadhani, Elliott M. Antman, Gary S. Friedman, Shashi K. Ramaiah and Vishal S. Vaidya
Journal of Pharmacology and Experimental Therapeutics January 1, 2021, 376 (1) 12-20; DOI: https://doi.org/10.1124/jpet.120.000204
Jump to section
- Article
- Abstract
- Introduction
- Multistakeholder Model Catalyzes Rapid Response to Global Pandemic Crisis
- Previous International Disasters Informed SARS-CoV-2 Emergency Preparedness
- End-to-End Biomarker Science to Accelerate Drug Discovery and Development
- Implementation of a Biomarker-Centric Strategy Based on Lessons Learned during a Global Pandemic
- Limitations of Adopting a Biomarker-Centric Approach
- Conclusions and Outlook
- Acknowledgments
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters